FY2023 EPS Estimates for Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) Reduced by Analyst

Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) – Equities researchers at Wedbush lowered their FY2023 earnings per share estimates for Eiger Biopharmaceuticals in a research report issued on Monday, August 12th. Wedbush analyst L. Moussatos now anticipates that the biotechnology company will post earnings of $0.61 per share for the year, down from their prior estimate of $0.62. Wedbush has a “Outperform” rating and a $35.00 price objective on the stock.

A number of other research firms also recently weighed in on EIGR. Zacks Investment Research upgraded shares of Eiger Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a research note on Tuesday. KeyCorp assumed coverage on shares of Eiger Biopharmaceuticals in a research note on Wednesday, June 26th. They set an “overweight” rating and a $10.72 price target on the stock. ValuEngine upgraded shares of Eiger Biopharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 2nd. Citigroup assumed coverage on shares of Eiger Biopharmaceuticals in a research note on Wednesday, June 26th. They set a “buy” rating and a $22.00 price target on the stock. Finally, LADENBURG THALM/SH SH reiterated a “buy” rating and set a $28.00 price target on shares of Eiger Biopharmaceuticals in a research note on Monday. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $28.34.

EIGR opened at $9.77 on Wednesday. Eiger Biopharmaceuticals has a fifty-two week low of $8.40 and a fifty-two week high of $15.33. The company has a debt-to-equity ratio of 0.62, a current ratio of 8.16 and a quick ratio of 8.16. The firm’s fifty day moving average price is $10.71 and its two-hundred day moving average price is $11.96. The company has a market capitalization of $240.47 million, a P/E ratio of -2.56 and a beta of 1.01.

Eiger Biopharmaceuticals (NASDAQ:EIGR) last posted its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.75) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.73) by ($0.02).

Large investors have recently modified their holdings of the company. Bank of Montreal Can acquired a new stake in shares of Eiger Biopharmaceuticals in the 2nd quarter valued at $28,000. Tower Research Capital LLC TRC boosted its stake in shares of Eiger Biopharmaceuticals by 1,719.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,895 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 4,626 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in shares of Eiger Biopharmaceuticals in the 2nd quarter valued at $113,000. Jane Street Group LLC acquired a new stake in shares of Eiger Biopharmaceuticals in the 4th quarter valued at $114,000. Finally, Wedbush Securities Inc. acquired a new stake in shares of Eiger Biopharmaceuticals in the 1st quarter valued at $179,000. Institutional investors own 80.68% of the company’s stock.

About Eiger Biopharmaceuticals

Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.

Featured Article: What Factors Can Affect Return on Equity?

Earnings History and Estimates for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.